Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.

ABSTRACT:

Background

Non-alcoholic fatty liver disease (NAFLD) is common both in obese and overweight patients. Fibroblast growth factor 19 (FGF19), an intestinal hormone, could play a role in the complex pathogenesis of NAFLD. The aim of our study was to investigate responses of FGF19 and bile acid (BA) synthesis after a body weight-adjusted oral fat tolerance test (OFTT) in overweight and obese NAFLD patients.

Methods

For this study, we recruited 26 NAFLD patients; 14 overweight (median BMI 28.3 kg/m²), 12 obese (35.3 kg/m²) and 16 healthy controls (24.2 kg/m²). All individuals received 1 g fat (Calogen®) per kg body weight orally. Serum concentrations of FGF19 were determined by ELISA. Concentrations of BAs and BA synthesis marker 7α-hydroxy-4-chole

SUBMITTER: Friedrich D 

PROVIDER: S-EPMC5987457 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature